Immune targeting molecules and uses thereof

A multispecific antibody, wherein the multispecific antibody comprises:

• a first binding domain that binds to CD28 and a second binding domain that binds to a second target that is not CD28, wherein the first binding domain that binds to CD28 comprises:
• (1) (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:31;
• and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:32;
• (2) (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:65;
• and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:66;
• (3) (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:99;
• and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:100;
• (4) (i) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:133;
• and (ii) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:
• 134;
• (5) (i) a VH comprising a VH CDR1 having an amino acid sequence selected from SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:19, and SEQ ID NO:25;
• a VH CDR2 having an amino acid sequence selected from SEQ ID NO:2, SEQ ID NO:8, SEQ ID NO:14, SEQ ID NO:20, and SEQ ID NO:26;
• a VH CDR3 having an amino acid sequence selected from SEQ ID NO:3, SEQ ID NO:9, SEQ ID NO:15, SEQ ID NO:21, and SEQ ID NO:27, and (ii) a VL comprising a VL CDR1 having an amino acid sequence selected from SEQ ID NO:4, SEQ ID NO:10, SEQ ID NO:16, SEQ ID NO:22, and SEQ ID NO:28, a VL CDR2 having an amino acid sequence selected from SEQ ID NO:5, SEQ ID NO:11, SEQ ID NO:17, SEQ ID NO:23, and SEQ ID NO:29, a VL CDR3 having an amino acid sequence selected from SEQ ID NO:6, SEQ ID NO:12, SEQ ID NO:18, SEQ ID NO:24, and SEQ ID NO:30,
• (6) (i) a VH comprising a VH CDR1 having an amino acid sequence selected from SEQ ID NO:35, SEQ ID NO:41, SEQ ID NO:47, SEQ ID NO:53, and SEQ ID NO:59, a VH CDR2 having an amino acid sequence selected from SEQ ID NO:36, SEQ ID NO:42, SEQ ID NO:48, SEQ ID NO:54, and SEQ ID NO:60, a VH CDR3 having an amino acid sequence selected from SEQ ID NO:37, SEQ ID NO:43, SEQ ID NO:49, SEQ ID NO:55, and SEQ ID NO:61, and (ii) a VL comprising a VL CDR1 having an amino acid sequence selected from SEQ ID NO:38, SEQ ID NO:44, SEQ ID NO:50, SEQ ID NO:56, and SEQ ID NO:62, a VL CDR2 having an amino acid sequence selected from SEQ ID NO:39, SEQ ID NO:45, SEQ ID NO:51, SEQ ID NO:57, and SEQ ID NO:63, a VL CDR3 having an amino acid sequence selected from SEQ ID NO:40, SEQ ID NO:46, SEQ ID NO:52, SEQ ID NO:58, and SEQ ID NO:64;
• (7) (i) a VH comprising a VH CDR1 having an amino acid sequence selected from SEQ ID NO:69, SEQ ID NO:75, SEQ ID NO:81, SEQ ID NO:87, and SEQ ID NO:93, a VH CDR2 having an amino acid sequence selected from SEQ ID NO:70, SEQ ID NO:76, SEQ ID NO:82, SEQ ID NO:88, and SEQ ID NO:94, a VH CDR3 having an amino acid sequence selected from SEQ ID NO:71, SEQ ID NO:77, SEQ ID NO:83, SEQ ID NO:89, and SEQ ID NO:95, and (ii) a VL comprising a VL CDR1 having an amino acid sequence selected from SEQ ID NO:72, SEQ ID NO:78, SEQ ID NO:84, SEQ ID NO:90, and SEQ ID NO:96, a VL CDR2 having an amino acid sequence selected from SEQ ID NO:73, SEQ ID NO:79, SEQ ID NO:85, SEQ ID NO:91, and SEQ ID NO:97;
• a VL CDR3 having an amino acid sequence selected from SEQ ID NO:74, SEQ ID NO:80, SEQ ID NO:86, SEQ ID NO:92, and SEQ ID NO:98;
• or
• (8) (i) a VH comprising a VH CDR1 having an amino acid sequence selected from SEQ ID NO:103, SEQ ID NO:109, SEQ ID NO:115, SEQ ID NO:121, and SEQ ID NO:127;
• a VH CDR2 having an amino acid sequence selected from SEQ ID NO:104, SEQ ID NO:110, SEQ ID NO:116, SEQ ID NO:122, and SEQ ID NO:128;
• a VH CDR3 having an amino acid sequence selected from SEQ ID NO:105, SEQ ID NO:111, SEQ ID NO:117, SEQ ID NO:123, and SEQ ID NO:129;
• and (ii) a VL comprising a VL CDR1 having an amino acid sequence selected from SEQ ID NO:106, SEQ ID NO:112, SEQ ID NO:118, SEQ ID NO:124, and SEQ ID NO:130;
• a VL CDR2 having an amino acid sequence selected from SEQ ID NO:107, SEQ ID NO:113, SEQ ID NO:119, SEQ ID NO:125, and SEQ ID NO:131;
• a VL CDR3 having an amino acid sequence selected from SEQ ID NO:108, SEQ ID NO:114, SEQ ID NO:120, SEQ ID NO:126, and SEQ ID NO:132.

A process for making an antibody that binds to more than one target molecule, the molecule comprising:

• a step for performing a function of obtaining a binding domain capable of binding to CD28 on the surface of a cell;
• a step for performing a function of obtaining a binding domain capable of binding to a second target antigen on a second cell;
• and a step for performing a function of providing an antibody capable of binding to a CD28 on the surface of a cell and a second target antigen on a second cell;
• optionally wherein the step for performing a function of obtaining a binding domain capable of binding to a second target antigen is repeated n times and further comprising n steps for performing a function of providing a binding domain capable of binding to CD28 on the surface of a cell and n number of target molecules, wherein n is at least 2.